Amneal Pharmaceuticals, Inc. (AMRX): Operating Income
$394.10M
Year ended 2025-12-31
$453.92M
Trailing 12 months to 2026-06-30
+34.0%
5-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $394.10M | +58.1% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $249.33M | +22.0% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $204.37M | n/m | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | -$94.93M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $152.72M | +67.5% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $91.16M | n/m | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | -$248.68M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$19.67M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $245.10M | -14.0% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $284.88M | n/a | 2019-03-01, From 2016-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $394.10M | +58.1% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.49B | +8.4% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $409.48M | -15.4% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $501.58M | n/m |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $1.56B | +20.7% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$699.78M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | -$1.12B | n/m |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | -$430.24M | n/m |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $866.93M | n/m |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗